Clinical Trials
44 trialsBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
INTUITT-NF2
Massachusetts General Hospital
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
Massachusetts General Hospital
SJFAMILY
St. Jude Children's Research Hospital
MERLIN_001
SkylineDx
NF110
University of Alabama at Birmingham
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
PRG Science & Technology Co., Ltd.
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Massachusetts General Hospital
Study of Aspirin in Patients With Vestibular Schwannoma
Massachusetts Eye and Ear Infirmary
Doxycycline in Cutaneous Schwannoma (NF2)
Massachusetts Eye and Ear Infirmary
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Massachusetts Eye and Ear Infirmary
POPLAR-NF2
Recursion Pharmaceuticals Inc.
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Leiden University Medical Center
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Jonsson Comprehensive Cancer Center
Neurofibromatosis (NF) Registry Portal
The Children's Tumor Foundation
Vestibular Precision: Physiology & Pathophysiology
Massachusetts Eye and Ear Infirmary
MERLIN
Novartis
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Icotinib
Beijing Tiantan Hospital
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)
NYU Langone Health
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
University of Alabama at Birmingham
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
NYU Langone Health
Effect of Implant Position on Magnetic Resonance Image Distortion
Manchester University NHS Foundation Trust
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
National Institutes of Health Clinical Center (CC)
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Massachusetts Eye and Ear Infirmary
PTC299 for Treatment of Neurofibromatosis Type 2
PTC Therapeutics
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Centre Hospitalier Universitaire de Nice
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
National Cancer Institute (NCI)
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
Massachusetts General Hospital
Reliability of Functional Outcome Measures in Neurofibromatosis 2
Guy's and St Thomas' NHS Foundation Trust
NF2
University Hospital Tuebingen
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
AFINF2
Assistance Publique - Hôpitaux de Paris
Endostatin
Beijing Tiantan Hospital
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Massachusetts General Hospital
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
FDA Office of Orphan Products Development
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
FDA Office of Orphan Products Development
NF2 Natural History Consortium
Office of Rare Diseases (ORD)